Targeting BCR‐ABL with ponatinib causes cardiomyopathy, HF, and vascular occlusion,13 with mitochondrial toxicity,14 integrated stress response activation14 and S100A8/A9‐NLRP3‐interleukin (IL)‐1β‐mediated inflammation15 identified as key mechanisms in human iPSC and murine models.14, 15. This evidence concerns the gene IL1B and hydrops fetalis.